

ABN 53 075 582 740

11 November 2021

Section 708A Notice

This notice is given by Bionomics Limited (**Company**) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

The Company hereby confirms that it has today:

- (a) issued 8,000,000 fully paid ordinary shares at an issue price of \$0.06 (6 cents per warrant) as a result of the exercise of 8,000,000 unlisted warrants issued on 3 March 2021 (approved by shareholders on 26 August 2020);
- (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) Section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Released on authority of the Board

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin Company Secretary <u>CoSec@bionomics.com.au</u>

About Bionomics Limited

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions

www.bionomics.com.au